Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Comparing HF versus NF radiotherapy in early breast cancer

Sofia Rivera • 16 Oct 2024
ESMO 2024
Breast Cancer
HypoG-01

Sofia Rivera, MD, PhD, Institut Gustave Roussy, Villejuif, France, explains the difference between hypofractionated (HF) radiotherapy (RT), which uses higher doses per fraction to reduce treatment duration, and normofractionated (NF) radiotherapy, which delivers smaller doses over more sessions. The Phase III HypoG-01 trial (NCT03127995) compares three weeks of HF radiotherapy to five weeks of NF radiotherapy, investigating whether shorter treatment regimens can provide equivalent outcomes with increased convenience for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sofia Rivera

HypoG-01: hypofractionated versus normofractionated radiotherapy in early breast cancer
2:05
HypoG-01: hypofractionated versus normofractionated radiotherapy in early breast cancer
Sofia Rivera • 16 Sep 2024
Carbon footprint of the one week ultra hypofractionated breast radiotherapy workflow
3:10
Carbon footprint of the one week ultra hypofractionated breast radiotherapy workflow
Sofia Rivera • 23 May 2023
Optimizing ultra-hypofractionated breast RT: streamlined workflow reduces sessions & transportation
2:11
Optimizing ultra-hypofractionated breast RT: streamlined workflow reduces sessions & transportation
Sofia Rivera • 23 May 2023
The potential of moderately hypofractionated radiotherapy: analysis & future directions
1:24
The potential of moderately hypofractionated radiotherapy: analysis & future directions
Sofia Rivera • 23 May 2023

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals